Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals announced that CEO and Chairman Robert Bitterman will present an overview of the company's INTASYL siRNA platform and lead candidate PH-762 at a Renmark Financial Communications virtual non-deal roadshow. The live presentation and Q&A are scheduled for Tuesday, October 20, 2026 at 12 PM EDT, with a replay available on Renmark's website.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.